Targeting the akt/mtor signaling pathway by maprotiline leads to tumor suppression in T-cell lymphoma

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• T-cell lymphoma (TCL) is a significant malignancy with limited treatment options.
• The molecular drivers of TCL and potential therapeutic targets are not fully understood.
• Maprotiline, a norepinephrine reuptake inhibitor, is used for depression but its anti-cancer effects are unexplored.

Purpose of the Study:

• To investigate the anti-cancer potential of maprotiline in T-cell lymphoma.
• To elucidate the underlying molecular mechanisms of maprotiline's action in TCL.
• To explore maprotiline as a novel therapeutic strategy for TCL.

Main Methods:

• In vitro studies using TCL cell lines to assess proliferation, migration, and apoptosis.
• In vivo experiments using TCL xenograft mouse models to evaluate tumor suppression and safety.
• Analysis of the AKT/mTOR signaling pathway.
• Combination therapy studies with histone deacetylase inhibitors.

Main Results:

• Maprotiline significantly inhibited TCL cell proliferation and migration while inducing apoptosis.
• Maprotiline treatment suppressed tumor progression in vivo with minimal toxicity.
• Maprotiline regulates the AKT/mTOR signaling pathway in TCL cells.
• Maprotiline enhanced TCL cell sensitivity to histone deacetylase inhibitors.

Conclusions:

• Maprotiline demonstrates potent anti-TCL activity, offering a new therapeutic avenue.
• The AKT/mTOR pathway is a key mediator of maprotiline's anti-cancer effects in TCL.
• Maprotiline presents a promising strategy for combination therapy in T-cell lymphoma treatment.